Questions for webinar, page-7

Nice webinar. I think most of your qs were answered, apart of the ALA iNKT one.

IMU getting OV CF 33 FDA Fast Track Designation for Bile Duct Cancer and CHM targeting solid gastric types with CDH 17 as well soon I wouldn't be surprised to see an IMU / CHM onCARlytics based on CD17 developed.

A lot of work and achievements for the Ex- Kite and Amgen experts at CHM for an EV of less than $10m. Dr Litten just mentioned the USD 100m deals in that space where CHM is well placed in the front line with several assets. Again, GMB, Gastric and blood cancer solutions for USD 7m - OMG!!!

GLTA